Literature DB >> 1330038

Interrupting autocrine ligand-receptor binding: comparison between receptor blockers and ligand decoys.

K E Forsten1, D A Lauffenburger.   

Abstract

Stimulation of cell behavioral functions by ligand/receptor binding can be accomplished in autocrine fashion, where cells secrete ligand capable of binding to receptors on their own surfaces. This proximal secretion of autocrine ligands near the surface receptors on the secreting cell suggests that control of these systems by inhibitors of receptor/ligand binding may be more difficult than for systems involving exogenous ligands. Hence, it is of interest to predict the conditions under which successful inhibition of cell receptor binding by the autocrine ligand can be expected. Previous theoretical work using a compartmentalized model for autocrine cells has elucidated the conditions under which addition of solution decoys for the autocrine ligand can interrupt cell receptor/ligand binding via competitive binding of the secreted molecules (Forsten, K. E., and D. A. Lauffenburger. 1992. Biophys. J. 61:1-12.) We now apply a similar modeling approach to examine the addition of solution blockers targeted against the cell receptor. Comparison of the two alternative inhibition strategies reveals that a significantly lower concentration of receptor blockers, compared to ligand decoys, will obtain a high degree of inhibition. The more direct interruption scheme characteristic of the receptor blockers may make them a preferred strategy when feasible.

Mesh:

Substances:

Year:  1992        PMID: 1330038      PMCID: PMC1262218          DOI: 10.1016/S0006-3495(92)81661-2

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  12 in total

1.  Analysis of lateral diffusion from a spherical cell surface to a tubular projection.

Authors:  D A Berk; A Clark; R M Hochmuth
Journal:  Biophys J       Date:  1992-01       Impact factor: 4.033

Review 2.  Signal transduction by the platelet-derived growth factor receptor.

Authors:  L T Williams
Journal:  Science       Date:  1989-03-24       Impact factor: 47.728

3.  Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody.

Authors:  B Goldstein; R G Posner; D C Torney; J Erickson; D Holowka; B Baird
Journal:  Biophys J       Date:  1989-11       Impact factor: 4.033

4.  Autocrine growth induced by the insulin-related factor in the insulin-independent teratoma cell line 1246-3A.

Authors:  Y Yamada; G Serrero
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

5.  Inhibition of growth of human lung adenocarcinoma cell lines by anti-transforming growth factor-alpha monoclonal antibody.

Authors:  K Imanishi; K Yamaguchi; M Kuranami; E Kyo; T Hozumi; K Abe
Journal:  J Natl Cancer Inst       Date:  1989-02-01       Impact factor: 13.506

6.  Autocrine secretion and malignant transformation of cells.

Authors:  M B Sporn; G J Todaro
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

7.  Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha.

Authors:  U Rodeck; N Williams; U Murthy; M Herlyn
Journal:  J Cell Biochem       Date:  1990-10       Impact factor: 4.429

8.  Autocrine and paracrine growth factors in tumor growth: a mathematical model.

Authors:  S Michelson; J Leith
Journal:  Bull Math Biol       Date:  1991       Impact factor: 1.758

9.  Transforming protein of simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors.

Authors:  J S Huang; S S Huang; T F Deuel
Journal:  Cell       Date:  1984-11       Impact factor: 41.582

10.  Production of TGF-alpha and TGF-beta by cultured keratinocytes, skin and oral squamous cell carcinomas--potential autocrine regulation of normal and malignant epithelial cell proliferation.

Authors:  M Partridge; M R Green; J D Langdon; M Feldmann
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

View more
  8 in total

1.  Ligand accumulation in autocrine cell cultures.

Authors:  Michael I Monine; Alexander M Berezhkovskii; Elizabeth J Joslin; H Steven Wiley; Douglas A Lauffenburger; Stanislav Y Shvartsman
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

Review 2.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

3.  Real-time quantitative measurement of autocrine ligand binding indicates that autocrine loops are spatially localized.

Authors:  D A Lauffenburger; G T Oehrtman; L Walker; H S Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 4.  Molecular/cell engineering approach to autocrine ligand control of cell function.

Authors:  D A Lauffenburger; K E Forsten; B Will; H S Wiley
Journal:  Ann Biomed Eng       Date:  1995 May-Jun       Impact factor: 3.934

5.  CGRP and the Calcitonin Receptor are Co-Expressed in Mouse, Rat and Human Trigeminal Ganglia Neurons.

Authors:  Tayla A Rees; Andrew F Russo; Simon J O'Carroll; Debbie L Hay; Christopher S Walker
Journal:  Front Physiol       Date:  2022-05-10       Impact factor: 4.755

6.  Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.

Authors:  Susana Frago; Ryan D Nicholls; Madeleine Strickland; Jennifer Hughes; Christopher Williams; Lee Garner; Mirvat Surakhy; Rory Maclean; Dellel Rezgui; Stuart N Prince; Oliver J Zaccheo; Daniel Ebner; Sabina Sanegre; Sheng Yu; Francesca M Buffa; Matthew P Crump; Andrew Bassim Hassan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

7.  Increase in trigeminal ganglion neurons that respond to both calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in mouse models of chronic migraine and posttraumatic headache.

Authors:  Zhaohua Guo; Katherine Czerpaniak; Jintao Zhang; Yu-Qing Cao
Journal:  Pain       Date:  2021-05-01       Impact factor: 7.926

8.  Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain.

Authors:  Miles A Miller; Marcia L Moss; Gary Powell; Robert Petrovich; Lori Edwards; Aaron S Meyer; Linda G Griffith; Douglas A Lauffenburger
Journal:  Sci Rep       Date:  2015-10-19       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.